Technical Analyst, Vermilion Research

Joe Jasper

Technical Analyst

Technical and Quantitative Research

Vermilion Research

Vermilion’s objective is to deliver timely, actionable, and unique technical research to professional investors through the application of our various technical indicators.

Our research strategists seek to highlight securities which we believe are at major inflection points, based on our various technical and quantitative indicators, and offer asymmetric risk/return profiles. Our unique research methodology, centered on relative strength, enables our strategists to deliver superior investment recommendations.

Our process begins by organizing the universe of actively traded stocks into discrete sectors, then into industry groups. We then apply our technical and quantitative tools to identify developing price trends. Once attractive trends are identified within a selected sector or group, we screen for individual stocks which we believe offer the best risk/reward profile. We provide a historical perspective that often reveals, through our long-term charts, how price patterns often repeat themselves over time.

Technical Analysis

S&amp;P 500 Potential Support Levels. Current logical support levels we are monitoring include the December 2018 low of 2,346 and prior resistance in 2015-2016 at 2,130-2,200. The 2,346 level would make a lot of sense, however there is nothing that says we can’t be down 35% (coinciding with the 2,130-2,200 level) or more from the highs. Ultimately, COVID-19 is holding the market hostage and it likely will stay that way until the virus spread diminishes.

S&amp;P 500 Potential Support Levels. Current logical support levels we are monitoring include the December 2018 low of 2,346 and prior resistance in 2015-2016 at 2,130-2,200. The 2,346 level would make a lot of sense, however there is nothing that says we can’t be down 35% (coinciding with the 2,130-2,200 level) or more from the highs. Ultimately, COVID-19 is holding the market hostage and it likely will stay that way until the virus spread diminishes.

S&P 500 Technical Appraisal and Support Levels

Ongoing bullish developments continue to support our belief that we are in the early stages of a broad-based advance following a nearly 2-year consolidation period. In today’s report we highlight attractive Groups and stocks within Health Care: Biotech, Large-Cap, Biotech, Mid-Cap, Hospitals, and Rehab Services.

Ongoing bullish developments continue to support our belief that we are in the early stages of a broad-based advance following a nearly 2-year consolidation period. In today’s report we highlight attractive Groups and stocks within Health Care: Biotech, Large-Cap, Biotech, Mid-Cap, Hospitals, and Rehab Services.

U.S. Equity Strategy: Upgrading Health Care to Overweight

US IPOs and Secondary Offerings, IPO Boutique

IPO Boutique

US IPOs and Secondary Offerings

For more than 20 years, we have been providing research, analysis, commentary and ratings on US Equity Capital Markets to institutional investors (US IPOs and Secondary Offerings). Our vast network of contacts across the Equity Capital Markets and attention-to-detail sets us apart from our competitors.

Since 2012, we have achieved a successful hit rating on 89% of Buy-rated IPOs. The collective “Buy” ratings averaged a first trade of 16.3% above issue.Our Neutral Rated Deals averaged just 2% above the issue price at first trade.

Our written research includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

In addition, we provide a high-touch premium desk access which includes analyst access, as well as real time insights on US IPOs as well as secondary offerings.

IPOs and Secondary Offerings

Equity Capital Markets

Parabilis Medicines / Equity Capital Markets

<ul>
<li>Parabilis Medicines IPO sets terms at $17–$19 for 25M shares, supported by a $75M strategic investment from Regeneron Pharmaceuticals, signaling strong validation.</li>
<li>Clinical-Stage biotech targeting historically undruggable proteins via Helicon platform; lead asset zolucatetide shows strong early efficacy in desmoid tumors, including 74% objective response rate.</li>
<li>Pipeline expands into oncology targets ERG and ARON, with venture-backed ownership; IPO expected to draw specialized biotech and crossover investors in a “clubby” book.</li>
</ul>


Parabilis Medicines IPO sets terms at $17–$19 for 25M shares, supported by a $75M strategic investment from Regeneron Pharmaceuticals, signaling strong validation.
Clinical-Stage biotech targeting historically undruggable proteins via Helicon platform; lead asset zolucatetide shows strong early efficacy in desmoid tumors, including 74% objective response rate.
Pipeline expands into oncology targets ERG and ARON, with venture-backed ownership; IPO expected to draw specialized biotech and crossover investors in a “clubby” book.


Parabilis Medicines, Inc. (PBLS): Biotech Targeting Desmoid Tumor Sets Terms for IPO

<ul>
<li>Parabilis Medicines filed its IPO on May 19, updated offering terms on June 4, and is set to debut on June 10 as it transitions into a public biotech company. </li>
<li>The company plans to offer 25 million shares in a $17–$19 price range, implying an estimated $1.9 billion to $2.1 billion market capitalization at pricing.</li>
<li>The offering provides exposure to its Helicon™ platform targeting historically undruggable proteins, highlighted by early clinical validation in oncology indications.</li>
</ul>


Parabilis Medicines filed its IPO on May 19, updated offering terms on June 4, and is set to debut on June 10 as it transitions into a public biotech company. 
The company plans to offer 25 million shares in a $17–$19 price range, implying an estimated $1.9 billion to $2.1 billion market capitalization at pricing.
The offering provides exposure to its Helicon™ platform targeting historically undruggable proteins, highlighted by early clinical validation in oncology indications.


Parabilis Medicines, Inc. (PBLS): Peeking at the IPO Prospectus of a Peptide Therapeutic Company

A combination of, optimism surrounding U.S.-China trade talks, and Fed Chairman Powell’s comments have led to a continuation of the oversold bounce which began on 12/26, and the S&amp;P 500 is now trading just below the 12/19 pre-Fed rate hike area. ~2,350 on the S&amp;P 500 remains the support level to monitor. A retest of this low remains the most likely scenario, though it is far from a guarantee due to the potential for a “V” reversal. We examine an array of factors leading to our intact cautious outlook, and highlight attractive set-ups within Consumer Discretionary and Health Care Sectors.

A combination of, optimism surrounding U.S.-China trade talks, and Fed Chairman Powell’s comments have led to a continuation of the oversold bounce which began on 12/26, and the S&amp;P 500 is now trading just below the 12/19 pre-Fed rate hike area. ~2,350 on the S&amp;P 500 remains the support level to monitor. A retest of this low remains the most likely scenario, though it is far from a guarantee due to the potential for a “V” reversal. We examine an array of factors leading to our intact cautious outlook, and highlight attractive set-ups within Consumer Discretionary and Health Care Sectors.

U.S. Equity Strategy: Oversold Rally Continues

United States

Regeneron Pharmaceuticals, Inc. is a biopharmaceutical company that discovers, develops, and commercializes pharmaceutical products for the treatment of serious medical conditions. The Company has therapeutic candidates in clinical trials for the potential treatment of cancer, eye diseases, and inflammatory diseases, and has preclinical programs in other diseases and disorders.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Regeneron Pharmaceuticals (REGN US)

S&P 500 Technical Appraisal and Support Levels

S&P 500 Potential Support Levels. Current logical support levels we are monitoring include the December 2018 low of 2,346 and prior resistance...

Vermilion Research

U.S. Equity Strategy: Upgrading Health Care to Overweight

Ongoing bullish developments continue to support our belief that we are in the early stages of a broad-based advance following a nearly 2-year...

Vermilion Research

Parabilis Medicines, Inc. (PBLS): Biotech Targeting Desmoid Tumor Sets Terms for IPO

Parabilis Medicines IPO backed by Regeneron with strong early efficacy in desmoid tumors, expanding pipeline into oncology targets ERG and ARON.

IPO Boutique

Parabilis Medicines, Inc. (PBLS): Peeking at the IPO Prospectus of a Peptide Therapeutic Company

Parabilis Medicines set to debut as public biotech company on June 10 with IPO offering 25 million shares in $17-$19 price range, focusing on...

IPO Boutique

U.S. Equity Strategy: Oversold Rally Continues

A combination of, optimism surrounding U.S.-China trade talks, and Fed Chairman Powell’s comments have led to a continuation of the oversold bounce...

Vermilion Research

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)

S&P 500 Technical Appraisal and Support Levels

S&P 500 Potential Support Levels. Current logical support levels we are monitoring include the December 2018 low of 2,346 and prior resistance...

Vermilion Research

U.S. Equity Strategy: Upgrading Health Care to Overweight

Ongoing bullish developments continue to support our belief that we are in the early stages of a broad-based advance following a nearly 2-year...

Vermilion Research

Parabilis Medicines, Inc. (PBLS): Biotech Targeting Desmoid Tumor Sets Terms for IPO

​Parabilis Medicines IPO backed by Regeneron with strong early efficacy in desmoid tumors, expanding pipeline into oncology targets ERG and ARON.

IPO Boutique

Parabilis Medicines, Inc. (PBLS): Peeking at the IPO Prospectus of a Peptide Therapeutic Company

​Parabilis Medicines set to debut as public biotech company on June 10 with IPO offering 25 million shares in $17-$19 price range, focusing on...

IPO Boutique

U.S. Equity Strategy: Oversold Rally Continues

A combination of, optimism surrounding U.S.-China trade talks, and Fed Chairman Powell’s comments have led to a continuation of the oversold bounce...

Vermilion Research

Parabilis Medicines IPO backed by Regeneron with strong early efficacy in desmoid tumors, expanding pipeline into oncology targets ERG and ARON.

Parabilis Medicines set to debut as public biotech company on June 10 with IPO offering 25 million shares in $17-$19 price range, focusing on...